Inari Medical Plunged 15% After Mixed Q2 Earnings, Lifting FY21 Sales Guidance

Loading...
Loading...
  • Inari Medical Inc's NARI Q2 revenue was $63.5 million, more than doubled from $25.4 million in Q2 FY20, beating the consensus of $59.6 million.
  • The growth was driven by continued U.S. commercial expansion and new product introductions.
  • Gross margin expanded from 86.3% to 92.4%, primarily due to the impact of an idle capacity charge in Q2 FY20 of 2020 of $1.1 million, combined with the current quarter product mix and manufacturing efficiencies.
  • Operating expenses increased to $54.5 million, from $22.5 million, led by higher personnel-related costs.
  • Inari posted Q2 EPS of $0.07, a shift from a $(0.16) loss, but below the estimate of $0.08.
  • Cash, cash equivalents, and short-term investments were $176.1 million.
  • The FDA cleared FlowSaver, enabling bloodless thrombectomy with the use of Triever Catheters.
  • FY21 Guidance: Inari Medical has updated revenue guidance to $250 million - $255 million from the previous guidance of $240 million - $250 million.
  • SVB Leerink maintained the Outperform rating on Inari Medical but lowered the price target to $110 from $126.
  • Price Action: NARI shares closed down 15.53% at $71.10 on Wednesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CarePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...